Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytes.
Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytes.
复制标题
重组白细胞介素 3 治疗对人肺泡巨噬细胞和单核细胞的免疫调节作用。
DOI：
10.1097/00002371-199307000-00006
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
Bukowski,RM
中科院分区：
文献类型：
--
作者：
Thomassen,MJ;Antal,JM;Connors,MJ;McLain,D;Sandstrom,K;Meeker,DP;Budd,GT;Levitt,D;Bukowski,RM
The purpose of these studies was to examine the effects of in vivo and in vitro recombinant IL-3 treatment on alveolar macrophage and monocyte activities associated with antitumor and antimicrobial properties. Alveolar macrophages and blood monocytes from 6 patients receiving IL-3 (125-500 [mu] g/m2/day) subcutaneously were isolated before therapy and at various times during the 15 days of therapy. Results indicated that tumor necrosis factor-[alpha](TNF), interleukin-1 [beta](IL-1), and interleukin-6 (IL-6) secretion were enhanced from monocytes of all patients and from alveolar macrophages of patients receiving 500 [mu] g/m2/day IL-3. Constitutive cytokine gene expression was present before therapy, but further enhancement was not detectable during therapy, suggesting a rapid time course of cytokine gene transcription and translation. Serum neopterin levels were elevated 2-5-fold in all patients compatible with the presence of augmented monocyte/macrophage activity. Peak levels of neopterin did not coincide with peak levels of cytokine secretion. In vitro studies of IL-3-treated normal alveolar macrophage and monocyte populations demonstrated that IL-3 significantly augmented TNF and IL-6 secretion in monocytes, but not in alveolar macrophages. These differences in alveolar macrophage cytokine secretion observed after in vivo and in vitro IL-3 treatment may reflect the involvement of other cell populations in IL-3 modulation of alveolar macrophages in vivo. Monocytes, in contrast were comparably activated by IL-3 whether presented in vitro or in vivo.
